MBL and prediction of risk on chemotherapy induced febrile neutropenia in patients with a solid tumor.

MBL and prediction of risk on chemotherapy induced febrile neutropenia in patients with a solid tumor. - MBL and febrile neutropenia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35673

Enrollment

243

Registered

2012-02-15

Start date

2012-05-12

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile neutropenia fever after chemotherapy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Treatment with chemotherapy for solid malignancy

Exclusion criteria

Exclusion criteria: Treatment with growth factor supoort and/or antibiotics

Design outcomes

Primary

Measure	Time frame
To explore the association between MBL level at baseline and the incidence of febrile neutropenia.	—

Secondary

Measure	Time frame
To explore the prognostic value of MBL-genotype on the incidence and severity of febrile neutropenia To explore whether the MBL level is different prior to chemotherapy cycle 2 compared to baseline. To explore the association between MBL level at baseline and the severity of febrile neutropenia during the first course To explore the association between MBL level at baseline and the incidence and severity of febrile neutropenia during the first 2 courses To explore the association between MBL level at baseline and the incidence and severity of febrile neutropenia during the treatment period To explore the association between MBL level before the second course and the incidence and severity of febrile neutropenia during the 2nd course To describe the change in MBL levels during a FN episode. To explore the potential change in MBL levels during a FN episode to severity of FN.	—

Measure

Time frame

To explore the prognostic value of MBL-genotype on the incidence and severity of febrile neutropenia To explore whether the MBL level is different prior to chemotherapy cycle 2 compared to baseline. To explore the association between MBL level at baseline and the severity of febrile neutropenia during the first course To explore the association between MBL level at baseline and the incidence and severity of febrile neutropenia during the first 2 courses To explore the association between MBL level at baseline and the incidence and severity of febrile neutropenia during the treatment period To explore the association between MBL level before the second course and the incidence and severity of febrile neutropenia during the 2nd course To describe the change in MBL levels during a FN episode. To explore the potential change in MBL levels during a FN episode to severity of FN.

—

Countries

Netherlands

Outcome results